Navigation Links
Lexicon Pharmaceuticals and Fox Chase Publish Findings on Immune,Deficiency

THE WOODLANDS, Texas, June 08, 2007 /PRNewswire-FirstCall/ -- Lexicon Pharmaceuticals, Inc. today announced the publication of new findings from a joint research project with scientists at Fox Chase Cancer Center in Philadelphia, PA. Together with David L. Wiest, Ph.D., Lexicon researchers have discovered a novel and surprising role for ribosomal protein L22 (Rpl22) in the development of T lymphocytes. These findings have been published in the June issue of the journal Immunity.

Dr. Wiest and scientists at Lexicon Pharmaceuticals discovered that deletion of the ubiquitously expressed Rpl22 gene resulted in the up-regulation of p53, a key tumor suppressor gene that triggers apoptosis and cell death. Further, it was determined that this up-regulation of p53 was responsible for blocking alpha-beta+ T cell development thereby creating an immune-deficient state.

"The connection between Rpl22 and the p53-mediated apoptosis pathway is very exciting," said Dr. David Wiest, Member, Basic Science Division at Fox Chase Cancer Center. "If research confirms our theories, Rpl22 may prove to be an important biomarker for certain T cell immune deficiency diseases and some types of lymphoid cancers."

Rpl22 is one of several proteins that comprise the large subunit of eukaryotic ribosomes, cellular complexes that are responsible for translating messenger RNA and assembling proteins. Although not-required for translation, Rpl22 may play a role in protein synthesis or macromolecular assembly that is important for some cell types, but not others.

"These findings could help us to further define the pathways involved in T lymphocyte development and regulation," said Dr. Tamas Oravecz, Lexicon's Vice President of Immunology and Oncology. "While Rp122 will likely prove difficult for development as a classic drug target, understanding its role could contribute significantly to its potential as a biomarker for disease."

About Lexicon

Lexicon is a biopharmaceutical company focused on the discovery and development of breakthrough treatments for human disease. Lexicon currently has clinical programs underway for such areas of major unmet medical need as irritable bowel syndrome and cognitive disorders. The company has used its proprietary gene knockout technology to discover more than 100 promising drug targets and create an extensive pipeline of clinical and preclinical programs in the therapeutic areas of diabetes and obesity, cardiovascular disease, psychiatric and neurological disorders, cancer, immune system disorders and ophthalmic disease. To advance the development and commercialization of its programs, Lexicon is working both independently and through collaborators including Bristol-Myers Squibb Company, Genentech, Inc., N.V. Organon and Takeda Pharmaceutical Company Limited. For additional information about Lexicon and its programs, please visit http://www.lexpharma.com.

    Editor's Note:

    1.  The article, "Ablation of Ribosomal Protein L22 Selectively Impairs

        alpha-beta T Cell Development by Activation of a p53-Dependent

        Checkpoint" may be obtained with a subscription at

        http://www.immunity.com/content/current.

    2.  For more information on Dr. David Wiest, please visit Fox Chase Cancer

        Center's website at http://www.fccc.edu or Dr. Wiest's research page

        at http://www.fccc.edu/research/pid/wiest.

Safe Harbor Statement

This press release contains "forward-looking statements," including statements relating to Lexicon's growth and future operating results, discovery and development of products, strategic alliances and intellect ual property, as well as other matters that are not historical facts or information. All forward-looking statements are based on management's current assumptions and expectations and involve risks, uncertainties and other important factors, specifically including those relating to Lexicon's ability to successfully conduct preclinical and clinical development of its potential drug candidates, advance additional candidates into preclinical and clinical development, obtain necessary regulatory approvals, achieve its operational objectives, obtain patent protection for its discoveries and establish strategic alliances, as well as additional factors relating to manufacturing, intellectual property rights, and the therapeutic or commercial value of its drug candidates, that may cause Lexicon's actual results to be materially different from any future results expressed or implied by such forward-looking statements. Information identifying such important factors is contained under "Factors Affecting Forward-Looking Statements" and "Risk Factors" in Lexicon's annual report on Form 10-K for the year ended December 31, 2006, as filed with the Securities and Exchange Commission. Lexicon undertakes no obligation to update or revise any such forward-looking statements, whether as a result of new information, future events or otherwise.

CONTACT: Bobbie Faulkner, Manager, Investor Relations of LexiconPharmaceuticals, Inc., +1-281-863-3503, bfaulkner@lexpharma.com

Web site: http://www.lexpharma.com/

Ticker Symbol: (NASDAQ-NMS:LXRX)

Terms and conditions of use apply
Copyright © 2007 PR Newswire Association LLC. All rights reserved.
A United Business Media Company


'"/>




Related medicine technology :

1. Lexicon Develops Antibodies That Lower Triglycerides and Cholesterol as Potential New Therapy for Heart Disease
2. Lexicon-Genentech Collaboration Yields Potential Therapeutic Targets
3. BioSante Pharmaceuticals Announces New Findings for Potential Bird Flu Vaccine
4. Portola Pharmaceuticals Announces Positive Data from a Phase II Study of its Factor Xa Inhibitor at the XXI Congress of the International Society on Thrombosis and Haemostasis
5. Manhattan Pharmaceuticals Announces Results of Phase 2a Studies for Oral Oleoyl-estrone
6. Auxilium Pharmaceuticals to Present at the 2007 CEUT Emerging Growth Opportunities Conference
7. Sunesis Pharmaceuticals to Present at the C. E. Unterberg, Towbin Emerging Growth Conference
8. EPIX Pharmaceuticals to Present at the C.E. Unterberg, Towbin Emerging Growth Opportunities Conference
9. Pro-Pharmaceuticals Updates Progress of Clinical Trials & Davanat 505 (b)(2) Filings
10. Cosmo Pharmaceuticals Reports Positive Preliminary Phase II/III Data with Rifamycin MMX in Infectious Diarrhea
11. Portola Pharmaceuticals Announces Positive Phase II EXPERT Results and Additional Oral and Poster Presentations at the XXI Congress of the International Society on Thrombosis and Haemostasis (ISTH)
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/23/2016)... , June 23, 2016 ... "Pharmaceutical Excipients Market by Type (Organic Chemical (Sugar, ... Formulation (Oral, Topical, Coating, Parenteral) - Global Forecast to ... The global pharmaceutical excipients market ... at a CAGR of 6.1% in the forecast period ...
(Date:6/23/2016)... LOS ANGELES , June 23, 2016 /PRNewswire/ ... (NASDAQ: CAPR ), a biotechnology company ... first-in-class therapeutics, today announced that patient enrollment in ... progrEssion in Duchenne) has exceeded 50% of its ... its enrollment in the third quarter of 2016, ...
(Date:6/23/2016)... and INDIANAPOLIS , June 23, ... a Lilly Diabetes Tomorrow,s Leaders Scholarship is any indication, ... winners, announced today online at www.diabetesscholars.org by ... 1 diabetes stand in the way of academic and ... the Foundation,s scholarship program since 2012, and continues to ...
Breaking Medicine Technology:
(Date:6/26/2016)... Michigan (PRWEB) , ... June 26, 2016 , ... ... to fertility once they have been diagnosed with endometriosis. These women need a ... they also require a comprehensive approach that can help for preservation of fertility ...
(Date:6/25/2016)... ... June 25, 2016 , ... The temporary closing of Bruton Memorial Library on June ... , brings up a new, often overlooked aspect of head lice: the parasite’s ability to ... is not a common occurrence, but a necessary one in the event that lice have ...
(Date:6/25/2016)... ... 25, 2016 , ... As a lifelong Southern Californian, Dr. Omkar Marathe earned ... the David Geffen School of Medicine at UCLA. He trained in Internal Medicine at ... fellowship in hematology/oncology at the UCLA-Olive View-Cedars Sinai program where he had the opportunity ...
(Date:6/25/2016)... ... June 25, 2016 , ... Conventional wisdom preaches the benefits of moderation, whether ... latter, setting the bar too high can result in disappointment, perhaps even self-loathing. However, ... their goal. , Research from PsychTests.com reveals that behind the tendency ...
(Date:6/24/2016)... ... June 24, 2016 , ... June 19, 2016 is World Sickle Cell ... pain and the benefits of holistic treatments, Serenity Recovery Center of Marne, ... Cell Disease. , Sickle Cell Disease (SCD) is a disorder of the red blood ...
Breaking Medicine News(10 mins):